GlassScriptPhysician profile
Nitin Aggarwal
NPI 1407145402
$4,896.75
in general payments reported to CMS, 2019-2025
25 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.45 · 2020: $158 · 2021: $45.50 · 2022: $192 · 2023: $1,773 · 2024: $1,083 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291 · Travel and Lodging: $1,154 · Education: $27.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.74 |
| Travel and Lodging | $1,153.51 |
| Education | $27.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,834.40 | 2023-2025 | Interstim |
| Abbvie INC. | $742.59 | 2020-2025 | Viberzi, Linzess, Creon |
| Gilead Sciences, INC. | $403.74 | 2020-2025 | Livdelzi |
| Neuraxis, INC. | $371.29 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $274.54 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $255.16 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.65 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $171.89 | 2024-2025 | |
| Janssen Biotech, INC. | $129.30 | 2023-2025 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $62.55 | 2023-2024 | Zeposia |
| Alnylam Pharmaceuticals INC. | $57.88 | 2025 | Givlaari |
| Ironwood Pharmaceuticals, INC | $53.05 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $39.45 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $37.85 | 2024 | Dupixent |
| Orphalan INC | $35.86 | 2025 | Cuvrior |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $29.72 | 2020 | |
| Qol Medical, LLC | $29.68 | 2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $24.97 | 2025 | Iqirvo |
| Novo Nordisk INC | $24.34 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $23.99 | 2024 | |
| Aimmune Therapeutics, INC. | $22.85 | 2025 | Vowst |
| Ferring Pharmaceuticals INC. | $16.92 | 2022 | |
| Ardelyx, INC. | $16.32 | 2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Travere Therapeutics, INC. | $10.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.